Sergei Lipov, MD
Internal Medicine · Elgin, ILNPI 1982634127
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$933
- Lilly USA, LLC$850
- Johnson & Johnson$555
- Amgen$523
- Novo Nordisk$374
- AstraZeneca$267
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,028100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 56 | $933 |
| Lilly USA, LLC | 46 | $850 |
| Johnson & Johnson | 33 | $555 |
| Amgen(2 entities) | 29 | $523 |
| Novo Nordisk | 19 | $374 |
| AstraZeneca | 16 | $267 |
| GSK | 11 | $197 |
| Pfizer | 9 | $148 |
| Otsuka America Pharmaceutical, Inc. | 7 | $143 |
| Sanofi-aventis U.S. LLC | 7 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $120 |
| Kowa Pharmaceuticals America, Inc. | 7 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $97 |
| Bayer | 4 | $95 |
| Sumitomo Pharma America, Inc. | 4 | $83 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Sunovion Pharmaceuticals Inc. | 4 | $61 |
| Nestle Healthcare Nutrition Inc. | 2 | $57 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Supernus Pharmaceuticals, Inc. | 2 | $36 |
| Boehringer Ingelheim | 2 | $32 |
| Lundbeck LLC | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Corcept Therapeutics | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Vivus LLC | 1 | $10 |
How this compares
$5,028 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 73 | $105,429 |
| OzempicSemaglutide | 61 | $97,721 |
| EliquisApixaban | 92 | $93,538 |
| JardianceEmpagliflozin | 61 | $67,801 |
| GemtesaVibegron | 37 | $39,480 |
| EntrestoSacubitril/Valsartan | 42 | $29,865 |
| Invega SustennaPaliperidone Palmitate | 13 | $29,731 |
| TrulicityDulaglutide | 21 | $29,621 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $25,852 |
| XareltoRivaroxaban | 26 | $24,504 |
| Repatha SureclickEvolocumab | 28 | $23,131 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $18,366 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $16,742 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $12,959 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $9,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $850 | $135,05194 claims |
| Novo NordiskOzempic | $374 | $97,72161 claims |
| PfizerEliquis | $148 | $93,53892 claims |
| Boehringer IngelheimJardiance | $32 | $67,80161 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta | $197 | $57,177102 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $555 | $54,23539 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $83 | $39,48037 claims |
| AstraZenecaFarxiga | $267 | $8,70417 claims |
| AbbVieLinzess, Synthroid | $933 | $8,32454 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Elgin
- Michael HernandezElgin$26K
- Zaid JabbarOak Brook$1.2M
- Merle DiamondChicago$1.1M
- David ReckerLibertyville$868K
- Yazen JoudehOrland Park$661K
- Robert KushnerChicago$516K
- William CruikshankOak Lawn$431K
- Romeo UrsuaChicago$420K
- Shaina RozellChicago Ridge$366K
- Kristi Tough DesapriWinnetka$344K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.